• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对接受细菌性阴道病治疗的南非女性阴道拭子分离株甲硝唑耐药性的评估。

Evaluation of Metronidazole Resistance of Vaginal Swab Isolates from South African Women Treated for Bacterial Vaginosis.

作者信息

Schwebs Timo, Kieninger Ann-Katrin, Podpera Tisakova Lenka, Oberbauer Vera, Berdaguer Rocío, Mtshali Andile, Mzobe Gugulethu, Rompalo Anne, Mindel Adrian, Letsoalo Marothi, Garrett Nigel, Ngcapu Sinaye, Corsini Lorenzo

机构信息

BioNTech R&D (Austria) GmbH, Helmut-Qualtinger-Gasse 2, 1030 Vienna, Austria.

Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban 4013, South Africa.

出版信息

Antibiotics (Basel). 2024 Dec 14;13(12):1217. doi: 10.3390/antibiotics13121217.

DOI:10.3390/antibiotics13121217
PMID:39766607
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11672489/
Abstract

: The high recurrence rate of bacterial vaginosis (BV) after antibiotic treatment is at least partially attributed to resistant bacteria. The CAPRISA 083 (CAP083) study investigated the influence of metronidazole (MTZ) treatment on the vaginal microbiome in 56 South African women diagnosed with BV. To explore the etiology of recurrent BV in this cohort, we retrospectively analyzed vaginal swabs collected in CAP083 before and after MTZ treatment. : We isolated over 1200 bacterial strains, including , and , and determined the minimum inhibitory concentration (MIC) of MTZ and the resistance status according to CLSI and EUCAST guidelines. : At baseline, 64% (CLSI) of isolates were resistant to MTZ, rising to 80% after MTZ treatment by the 12-week visit. species consistently exhibited resistance of 100%, while maintained resistance rates of 78-91% across visits. strains varied, showing two susceptible isolates at baseline and one resistant isolate at the 6-week visit. Susceptible and resistant isolates were often isolated from the same swab, and 70% (CLSI) of participants had at least one resistant strain already at baseline. Sensitive isolates were not a predictor of an MTZ-mediated reduction in abundance. : Our data indicate that the 23% cure rate in CAP083 was associated with a combination of a high share of MTZ-resistant bacteria at baseline, a potentially insufficient MTZ dose regimen, and a constantly high average abundance of . Future research should explore novel therapeutic strategies to enhance treatment efficacy and combat antibiotic resistance.

摘要

细菌性阴道病(BV)在抗生素治疗后的高复发率至少部分归因于耐药菌。CAPRISA 083(CAP083)研究调查了甲硝唑(MTZ)治疗对56名被诊断为BV的南非女性阴道微生物群的影响。为了探究该队列中复发性BV的病因,我们回顾性分析了CAP083研究中MTZ治疗前后收集的阴道拭子。我们分离出1200多种细菌菌株,包括[具体菌株名称未给出],并根据CLSI和EUCAST指南确定了MTZ的最低抑菌浓度(MIC)和耐药状态。基线时,[具体菌株名称未给出]分离株中有64%(CLSI标准)对MTZ耐药,在12周随访时MTZ治疗后升至80%。[具体菌株名称未给出]物种始终表现出100%的耐药性,而[具体菌株名称未给出]在各次随访中耐药率维持在78 - 91%。[具体菌株名称未给出]菌株情况各异,基线时有两个敏感分离株,6周随访时有一个耐药分离株。敏感和耐药的[具体菌株名称未给出]分离株常从同一拭子中分离出来,70%(CLSI标准)的参与者在基线时就至少有一株耐药的[具体菌株名称未给出]菌株。敏感的[具体菌株名称未给出]分离株并非MTZ介导的[具体菌株名称未给出]丰度降低的预测指标。我们的数据表明,CAP083研究中23%的治愈率与基线时MTZ耐药菌比例高、MTZ剂量方案可能不足以及[具体菌株名称未给出]的平均丰度持续居高有关。未来的研究应探索新的治疗策略以提高治疗效果并对抗抗生素耐药性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84d4/11672489/5c66b45520ab/antibiotics-13-01217-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84d4/11672489/a20c010d0e7d/antibiotics-13-01217-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84d4/11672489/f85e41b50a72/antibiotics-13-01217-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84d4/11672489/b625ca33c9ef/antibiotics-13-01217-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84d4/11672489/513e66cbcbe7/antibiotics-13-01217-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84d4/11672489/29a0d2cbd0bd/antibiotics-13-01217-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84d4/11672489/4d83810b29f4/antibiotics-13-01217-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84d4/11672489/5c66b45520ab/antibiotics-13-01217-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84d4/11672489/a20c010d0e7d/antibiotics-13-01217-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84d4/11672489/f85e41b50a72/antibiotics-13-01217-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84d4/11672489/b625ca33c9ef/antibiotics-13-01217-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84d4/11672489/513e66cbcbe7/antibiotics-13-01217-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84d4/11672489/29a0d2cbd0bd/antibiotics-13-01217-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84d4/11672489/4d83810b29f4/antibiotics-13-01217-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84d4/11672489/5c66b45520ab/antibiotics-13-01217-g007.jpg

相似文献

1
Evaluation of Metronidazole Resistance of Vaginal Swab Isolates from South African Women Treated for Bacterial Vaginosis.对接受细菌性阴道病治疗的南非女性阴道拭子分离株甲硝唑耐药性的评估。
Antibiotics (Basel). 2024 Dec 14;13(12):1217. doi: 10.3390/antibiotics13121217.
2
Dynamics and diversity of vaginal microbiota in bacterial vaginosis among Thai patients treated with metronidazole.甲硝唑治疗的泰国细菌性阴道病患者阴道微生物群的动态变化与多样性
J Infect Public Health. 2025 Feb;18(2):102646. doi: 10.1016/j.jiph.2024.102646. Epub 2025 Jan 3.
3
Exploring potential of vaginal Lactobacillus isolates from South African women for enhancing treatment for bacterial vaginosis.探索南非女性阴道乳杆菌分离株在增强细菌性阴道病治疗方面的潜力。
PLoS Pathog. 2020 Jun 4;16(6):e1008559. doi: 10.1371/journal.ppat.1008559. eCollection 2020 Jun.
4
Metronidazole response profiles of Gardnerella species are congruent with phylogenetic and comparative genomic analyses.加德纳菌属物种的甲硝唑反应谱与系统发育和比较基因组分析结果一致。
Genome Med. 2025 Mar 25;17(1):28. doi: 10.1186/s13073-025-01446-4.
5
Susceptibility of bacterial vaginosis (BV)-associated bacteria to secnidazole compared to metronidazole, tinidazole and clindamycin.与甲硝唑、替硝唑和克林霉素相比,细菌性阴道病(BV)相关细菌对塞克硝唑的敏感性。
Anaerobe. 2017 Oct;47:115-119. doi: 10.1016/j.anaerobe.2017.05.005. Epub 2017 May 15.
6
Vaginal abundance is associated with outcome in antibiotic treatment of bacterial vaginosis and capable of inhibiting .阴道分泌物丰度与细菌性阴道病抗生素治疗结局相关,并具有抑制作用。
Front Cell Infect Microbiol. 2022 Nov 22;12:1033431. doi: 10.3389/fcimb.2022.1033431. eCollection 2022.
7
Preclinical Data on the -Specific Endolysin PM-477 Indicate Its Potential to Improve the Treatment of Bacterial Vaginosis through Enhanced Biofilm Removal and Avoidance of Resistance.关于 - 特异性内切酶 PM-477 的临床前数据表明,它有可能通过增强生物膜清除和避免耐药性来改善细菌性阴道病的治疗。
Antimicrob Agents Chemother. 2022 May 17;66(5):e0231921. doi: 10.1128/aac.02319-21. Epub 2022 Apr 13.
8
Efficacy of oral metronidazole with vaginal clindamycin or vaginal probiotic for bacterial vaginosis: randomised placebo-controlled double-blind trial.口服甲硝唑联合阴道克林霉素或阴道益生菌治疗细菌性阴道病的疗效:随机安慰剂对照双盲试验。
PLoS One. 2012;7(4):e34540. doi: 10.1371/journal.pone.0034540. Epub 2012 Apr 3.
9
Association of key species of vaginal bacteria of recurrent bacterial vaginosis patients before and after oral metronidazole therapy with short- and long-term clinical outcomes.口服甲硝唑治疗前后复发性细菌性阴道病患者阴道关键细菌与短期和长期临床结局的相关性。
PLoS One. 2022 Jul 28;17(7):e0272012. doi: 10.1371/journal.pone.0272012. eCollection 2022.
10
[Biotypes and antibiotic resistance patterns of Gardnerella vaginalis strains isolated from healthy women and women with bacterial vaginosis].[从健康女性和细菌性阴道病女性中分离出的阴道加德纳菌菌株的生物型和抗生素耐药模式]
Mikrobiyol Bul. 2007 Jan;41(1):21-7.

本文引用的文献

1
Defining Vaginal Community Dynamics: daily microbiome transitions, the role of menstruation, bacteriophages, and bacterial genes.定义阴道群落动态:日常微生物组转变、月经的作用、噬菌体和细菌基因。
Microbiome. 2024 Aug 19;12(1):153. doi: 10.1186/s40168-024-01870-5.
2
Gardnerella Species and Their Association With Bacterial Vaginosis.加德纳菌属物种及其与细菌性阴道病的关系。
J Infect Dis. 2024 Jul 25;230(1):e171-e181. doi: 10.1093/infdis/jiae026.
3
diversity and ecology in pregnancy and preterm birth.妊娠和早产中的多样性和生态学。
mSystems. 2024 Jun 18;9(6):e0133923. doi: 10.1128/msystems.01339-23. Epub 2024 May 16.
4
A citizen-science-enabled catalogue of the vaginal microbiome and associated factors.基于公民科学的阴道微生物组及其相关因素目录。
Nat Microbiol. 2023 Nov;8(11):2183-2195. doi: 10.1038/s41564-023-01500-0. Epub 2023 Oct 26.
5
Understanding and Preventing Recurring Bacterial Vaginosis: Important Considerations for Clinicians.了解和预防复发性细菌性阴道病:临床医生的重要考量因素
Int J Womens Health. 2023 Aug 9;15:1317-1325. doi: 10.2147/IJWH.S383333. eCollection 2023.
6
Bacterial vaginosis: a review of approaches to treatment and prevention.细菌性阴道病:治疗与预防方法综述
Front Reprod Health. 2023 May 31;5:1100029. doi: 10.3389/frph.2023.1100029. eCollection 2023.
7
Bacterial Vaginosis-Vaginal Polymicrobial Biofilms and Dysbiosis.细菌性阴道病-阴道多微生物生物膜和微生态失调。
Dtsch Arztebl Int. 2023 May 19;120(20):347-354. doi: 10.3238/arztebl.m2023.0090.
8
The Role of Antimicrobial Resistance in Refractory and Recurrent Bacterial Vaginosis and Current Recommendations for Treatment.抗菌药物耐药性在难治性和复发性细菌性阴道病中的作用及当前治疗建议
Antibiotics (Basel). 2022 Apr 9;11(4):500. doi: 10.3390/antibiotics11040500.
9
Preclinical Data on the -Specific Endolysin PM-477 Indicate Its Potential to Improve the Treatment of Bacterial Vaginosis through Enhanced Biofilm Removal and Avoidance of Resistance.关于 - 特异性内切酶 PM-477 的临床前数据表明,它有可能通过增强生物膜清除和避免耐药性来改善细菌性阴道病的治疗。
Antimicrob Agents Chemother. 2022 May 17;66(5):e0231921. doi: 10.1128/aac.02319-21. Epub 2022 Apr 13.
10
Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation.乳杆菌属的半胱氨酸依赖性是阴道微生物组调节的一个潜在治疗靶点。
Nat Microbiol. 2022 Mar;7(3):434-450. doi: 10.1038/s41564-022-01070-7. Epub 2022 Mar 3.